SEC Form 4 · accession 0001315406-15-000010
BIO-RAD LABORATORIES, INC. · BIO BIO.B
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alice N Schwartz
Director · 10% Owner
Period of report
Mar 11, 2015
Accepted (ET)
Mar 12, 2015 · 6:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000012208
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Bio-Rad A Common StockF1 | Mar 11, 2015 | S | 37,680 | $133.95 | D | 1,835,971 | I | By Alice N. Schwartz Revocable Trust |
| Bio-Rad A Common StockF2 | Mar 11, 2015 | S | 22,320 | $134.17 | D | 1,813,651 | I | By Alice N. Schwartz Revocable Trust |
| Bio-Rad A Common Stock | holding | — | — | — | 90 | I | By David Schwartz Exemption Trust | |
| Bio-Rad A Common Stock | holding | — | — | — | 240 | I | By David Schwartz Exempt Marital Trust | |
| Bio-Rad A Common Stock | holding | — | — | — | 898,931 | I | By David Schwartz Non-Exempt Marital Trust | |
| Bio-Rad A Common Stock | holding | — | — | — | 34,311 | I | By Charitable Remainder Unitrust | |
| Bio-Rad B Common Stock | holding | — | — | — | 440,630 | I | By Alice N. Schwartz Revocable Trust | |
| Bio-Rad B Common Stock | holding | — | — | — | 57,000 | I | By David Schwartz Non-Exempt Marital Trust | |
| Bio-Rad B Common StockF3 | holding | — | — | — | 4,060,054 | I | By Blue Raven Partners, L.P. | |
| Bio-Rad B Common StockF4 | holding | — | — | — | 41,176 | I | By DANSA Partners Limited |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.05 to $134.00, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.01 to $134.54, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The shares are held by a limited partnership of which the reporting person is a limited and general partner.
- F4The shares are held by a limited partnership of which the reporting person is a general partner.